You can seek FDA approval to launch a generic drug before the expiration of ADEMPAS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADEMPAS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADEMPAS:-

You can seek FDA approval to launch a generic drug before the expiration of BRILINTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BRILINTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BRILINTA:-

You can seek FDA approval to launch a generic drug before the expiration of GILENYA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GILENYA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GILENYA:-

You can seek FDA approval to launch a generic drug before the expiration of JADENU's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JADENU's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JADENU:-

You can seek FDA approval to launch a generic drug before the expiration of JULUCA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JULUCA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JULUCA:-

You can seek FDA approval to launch a generic drug before the expiration of LEXISCAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LEXISCAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LEXISCAN:-

You can seek FDA approval to launch a generic drug before the expiration of NERLYNX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NERLYNX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NERLYNX:-

You can seek FDA approval to launch a generic drug before the expiration of NOXAFIL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NOXAFIL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NOXAFIL:-

You can seek FDA approval to launch a generic drug before the expiration of ODEFSEY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ODEFSEY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ODEFSEY:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of REVLIMID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REVLIMID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REVLIMID:-

You can seek FDA approval to launch a generic drug before the expiration of SELZENTRY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SELZENTRY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SELZENTRY:-

You can seek FDA approval to launch a generic drug before the expiration of SYNRIBO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SYNRIBO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SYNRIBO:-

You can seek FDA approval to launch a generic drug before the expiration of TORISEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TORISEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TORISEL:-

You can seek FDA approval to launch a generic drug before the expiration of TYKERB's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TYKERB's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TYKERB:-